| Print

Tvardi Therapeutics Inc (TVRD)

Common Shares
Sell: $2.80|Buy: $3.30|Change: 0.06 (-2.03%)
This investment is classed as a complex financial instrument. These types of investments carry higher risks and can be more difficult to understand. They are intended for experienced investors who have a good understanding of how these investments work. Read more about complex financial instruments.

This share can be held in a Dealing accountStocks and shares ISALifetime ISASIPP

Company profile

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Address




Website

https://www.tvarditherapeutics.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Tvardi Therapeutics Inc Fourth Quarter Earnings Results for 20262027-03-31T00:00:00
Tvardi Therapeutics Inc Annual Report for 20262027-03-31T00:00:00
Tvardi Therapeutics Inc Third Quarter Earnings Results for 20262026-11-13T00:00:00
Tvardi Therapeutics Inc Second Quarter Earnings Results for 20262026-08-14T00:00:00
Tvardi Therapeutics Inc First Quarter Earnings Results for 20272026-05-13T00:00:00
Tvardi Therapeutics Inc First Quarter Earnings Results for 20262026-05-13T00:00:00
Tvardi Therapeutics Inc Annual General Meeting for 20252026-04-30T00:00:00

Previous key dates

NameKey Date
Tvardi Therapeutics Inc Annual General Meeting for 20252026-04-30T00:00:00
Tvardi Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-31T00:00:00
Tvardi Therapeutics Inc Annual Report for 20252026-03-31T00:00:00
Barclays 28(th) Annual Global Healthcare Conference2026-03-10T14:00:00
TD Cowen 46(th) Annual Health Care Conference2026-03-03T13:50:00
Oppenheimer 36(th) Annual Healthcare Life Sciences Conference2026-02-25T10:40:00
JonesTrading C-Suite Fireside Chat Series2026-02-19T11:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-15T12:00:00
Piper Sandler 37th Annual Healthcare Conference2025-12-02T12:00:00
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference2025-11-18T09:30:00
Tvardi Therapeutics Inc Third Quarter Earnings Results for 20252025-11-13T00:00:00
Cantor Global Healthcare Conference2025-09-04T14:10:00
Tvardi Therapeutics Inc Second Quarter Earnings Results for 20252025-08-14T00:00:00
Tvardi Therapeutics Inc First Quarter Earnings Results for 20252025-05-13T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.